Stanton Rowe Joins Gradient Denervation Technologies Board

Gradient Denervation Technologies has appointed medical device serial entrepreneur Stanton Rowe to its Board of Directors.

“Gradient is at a critical point in our development as we build our clinical experience with our ultrasound-based pulmonary artery denervation technology,” Gradient CEO Martin Grasse said. “I’m delighted to have Stan joining us and am looking forward to leveraging his deep experience to help guide the company in our next phase.”

Rowe has developed multiple medical technologies through his current incubator—Nidus Biomedical— and with his prior incubator, NXT Biomedical. He was chief scientific officer of Edwards Lifesciences and was co-founder and CEO of Percutaneous Valve Technologies, developer of the first transcatheter aortic valve replacement device, which was later acquired by Edwards.

“I’m very excited to join Gradient and work with the company to bring this technology to patients,” Rowe stated. “Gradient’s early experience with pulmonary denervation is promising and I see great potential for this system to provide a new treatment option for these underserved patients.”

Gradient also announced U.S. Food and Drug Administration (FDA) approval for expanding the PreVail-PH2 Early Feasibility Study based on initial cohort results. The study is actively enrolling patients with WHO Group 2 Pulmonary Hypertension at U.S. centers and is recruiting additional clinical centers with heart failure and pulmonary hypertension expertise.

Gradient Denervation Technologies is developing a minimally invasive device for treating pulmonary hypertension in heart failure patients. Gradient leverages intellectual property developed at Stanford University. The Gradient device is for investigational use only and is not approved for commercial use anywhere in the world.